Advertisement
U.S. markets closed

Mind Medicine (MindMed) Inc. (MMED.NE)

Cboe CA - Cboe CA Real Time Price. Currency in CAD
14.90+1.29 (+9.48%)
At close: 03:55PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.61
Open12.50
Bid14.60 x N/A
Ask14.95 x N/A
Day's Range11.60 - 15.07
52 Week Range3.30 - 16.40
Volume81,492
Avg. Volume65,770
Market Cap1.05B
Beta (5Y Monthly)2.53
PE Ratio (TTM)N/A
EPS (TTM)-3.31
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MMED.NE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      MindMed to Present at Upcoming April Medical Conferences

      NEW YORK, April 02, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

    • Business Wire

      MindMed Announces Voluntary Delisting from Cboe Canada

      NEW YORK, April 01, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada. MindMed’s common shares will continue to be liste

    • Business Wire

      MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference

      NEW YORK, March 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will host one on one investor meetings at the Leerink Partners 2024 Global Biopharma Conference, which will be held in Miami, FL from March 11-13, 2024.